Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation

ABSTRACT Currently, there are four CAR-T products commercially available on the market. CAR-T cells have shown high remission rates and they represent an effective treatment option for patients with resistant or refractory B cell malignancies. Approval of these cell therapy products came after an extended period of preclinical evaluation that demonstrated unprecedented efficacy in this difficult-to-treat patient population. This review article outlines the main preclinical evaluations needed for CAR T cell product development.

Saved in:
Bibliographic Details
Main Authors: Picanço-Castro,Virginia, Bonamino,Martín Hernan, Ramos,Rodrigo Nalio, Guerino-Cunha,Renato L, Oliveira,Theo Gremen M, Rego,Eduardo M
Format: Digital revista
Language:English
Published: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) 2021
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792021000500054
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792021000500054

Similar Items